Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Jo Howard, MB Bchir, MRCP, FRCPath
Healthcare Provider Head of Red Cell/Sickle Cell Service
Guy's and St Thomas'
NHS Foundation Trust
Great Maze Pond
London, United Kingdom
Jo Howard, MB BChir, MRCP, FRCPath, became a consultant at Guy’s and St Thomas’ NHS Foundation Trust, in 2007, and is now Head of the red cell/sickle cell service. She was a consultant at Central Middlesex Hospital (North West London Hospitals) earlier where she ran their sickle cell service. Jo receives referrals for patients with complications of sickle cell disease from all over the UK. She has lectured on sickle cell disease at national conferences, including the British Society of Haematology, Royal College of Pathology, Royal College of Obstetrics and Gynaecology and British Thoracic Society. She is involved in several research projects in sickle cell disease and has published in this area. Jo is on the steering committees for the UK Forum for Haemoglobin Disorders, the National Haemoglobinpathy Registry and the British Committee for Standards in Haematology (General Haematology) and is the lead for Adult Peer Review for haemoglobinopathies.
Representative Publications:
Hydroxyurea (hydroxycarbamide) for sickle cell disease
+myBinderRelated Content
-
Edith Peterson Mitchell, MDEdith Peterson Mitchell, MD, is board ce...
-
Clinical Transformation in Care for Patients With Sickle Cell Disease at an Urban Academic Medical CenterThis article demonstrates effects on uti...
-
Vanderbilt University Medical CenterThe Vanderbilt-Meharry-Matthew Walker Ce...
-
Yvonne Carroll, RN, JDYvonne M. Carroll, RN, JD is the Directo...
-
Sickle Cell Disease: Tipping the Balance of Genomic Research to Catalyse Discoveries in AfricaThe completion of the Human Genome Proje...
-
Webinar Series: Sickle Cell Science: Path to Progress – Serving the Sickle Cell Disease Community Here and Abr...To commemorate Sickle Cell Awareness Mon...
-
Global Sickle Cell Disease Treatment Market 2019–2023| Evolving Opportunities with ADDMEDICA and Bristol-Myers Squ...The global sickle cell disease treatment...
